Loading…
Radiolabeling of monoclonal antibody B43.13 with rhenium-188 for immunoradiotherapy
In this study we report a novel method for direct radiolabeling of monoclonal antibody B43.13 (MAb-B43.13) with 188Re and have evaluated the product's radiochemical, biochemical, immunochemical and selected biological properties. 188ReMAbB43.13 was readily prepared by the addition of generato...
Saved in:
Published in: | Applied radiation and isotopes 1997-07, Vol.48 (7), p.899-906 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | In this study we report a novel method for direct radiolabeling of monoclonal antibody B43.13 (MAb-B43.13) with
188Re and have evaluated the product's radiochemical, biochemical, immunochemical and selected biological properties.
188ReMAbB43.13 was readily prepared by the addition of generator produced perrhenate to a preformulated antibody vial after an optimal amount of supplemental stannous ion, in the form of stannous tartrate, was added. The final radiolabeled product retained its biochemical purity (as determined by size-exclusion HPLC and R/NR-SDS-PAGE), its immunoreactivity (as determined by immunoassay) and presented with a typical stability (in the presence of serum and cysteine) and biodistribution (in tumored mice) profile. The evaluation of the product for immunoradiotherapy of ovarian cancer in a clinical setting requires further studies. |
---|---|
ISSN: | 0969-8043 1872-9800 |
DOI: | 10.1016/S0969-8043(97)00025-0 |